ABSTRACT
The FDA has concerns about a very small piece of the PBM puzzle. Much of what is being talked about here today involves economic issues that others in the federal government pay attention to. We wish them well as they "follow the money." A pharmaceutical executive said to me the first day I met with someone from a PBM being purchased by a drug company regulated by the FDA, "Look, Mary, right now, out of $1 in health care costs, drugs account for only 7¢. We are going after the other 93¢."
